DRUG USE EVALUATION OF CORTICOSTEROIDSIN SYSTEMIC LUPUS ERYTHEMATOSUS OUTPATIENTS

Abstract

Corticosteroids was the mainstay therapy for SLE, an autoimmune chronic desease. Prolonged use of Corticosteroid caused many side effects’ risk. This study was aimed to evaluate corticosteroid drug use in SLE outpatients. This study was conducted on April 2017 to August 2017. Cross sectional design was used and presented with analytical descriptive. The result is, 192 SLE outpatients pass the inclusion criteria and 98,96% are women. Methylprednisolon per oral is the most corticosteroid used for SLE outpatients, combine with 1 other immnunsuppresant ( 65,10  %) and combine with 2 other immunsuppresant ( 8,33% ). From  BMI, 26,05% subjects are overweight, perhaps because of corticosteroids side effect, such as weight gain. More than a half SLE outpatients (58,33%) get Calcium supplement and vitamin D3 as prophylactive for osteoporosis because of prolonged use of  corticosteroid and  61 SLE outpatients get drug for gastrointestinal use to avoid peptic ulcer. There are   44  cases of  potential corticosteroid interaction with other drug that are given together, the most are corticosteroid and aspirin interaction, on 14 patients.